CERUS CORP - 8-K Filing
Cerus Corporation reports Q3 2026 total revenue of $64.0 million and announces positive topline Phase 3 RedeS results for INTERCEPT Blood System. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $CERS
Read the full article at SEC EDGAR
Part of the story CRH PUBLIC LTD CO - 8-K Filing (20 articles)